A solid pharmaceutical composition for oral administration comprising a cyclosporin and an anionic surfactant, preferably sodium lauryl sulfate, wherein the amount of anionic surfactant is at least about forty percent of the minimum amount needed to dissolve the cyclosporin in water.
The bioavailability of fenofibrate is improved by making a solid dispersion of a disentegrant in the fenofibrate. Method of making said solid dispersion comprising melting the fenofibrate, blending the disintegrant into the melt, and resolidifying the mixture.
Improved process to produce magnesium omeprazole substantially amorphous with pharmaceutically acceptable low level of methanol and solid pharmaceutical compositions.
A process of producing the magnesium salt of an enantiomer of omeprazole, said process comprising the steps of: i) reacting magnesium with a lower alcohol to produce magnesium alkoxide in solution in the lower alcohol as solvent, ii) adding the neutral form of the enantiomer of omeprazole to the sol ...
A controlled-release pharmaceutical composition for oral administration comprising a multitude of granules made by dissolving or dispersing a drug and a water-insoluble polymer in a molten carrier, solidifying the resultant material, and grinding the resultant solid into granules.
A pharmaceutical tablet comprising a core and a film coating wherein the core comprises an NSAID and the film coating comprises a polymer and misoprostol.
Pharmaceutical compositions in the form of an emulsion preconcentrate or microemulsion preconcentrate which comprise a cyclosporin as active ingredient, acetylated monoglyceride as lipophilic solvent, a surfactant, and optionally a hydrophilic solvent.
A pharmaceutical tablet which incorporates two smaller tablets, one of which comprises an NSAID and the other of which comprises misoprostol.
A pharmaceutical composition for oral administration comprising a co-micronized mixture of fenofibrate and a solid excipient that is not a surfactant.